Status:

UNKNOWN

Effect of Proton Pump Inhibitor on Residual Platelet Reactivity After Clopidogrel in Homogenous Genetic Strata

Lead Sponsor:

Università degli Studi di Ferrara

Conditions:

Coronary Stenting

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This study aims to prospectively assess whether there is an interaction between genetic status in terms of 2C19 activity and residual platelet reactivity after clopidogrel intake in patients who under...

Detailed Description

In managing patients who undergo percutaneous coronary intervention (PCI), rapid and predictable platelet inhibition for all patients is an important therapeutic goal. Determining the optimal dose of ...

Eligibility Criteria

Inclusion

  • All comer patients undergoing PCI will be recruited on a consecutive basis.
  • • Patients will undergo screening before or soon after PCI depending on their clinical presentation as follows:
  • STEMI patients will receive upstream treatment with 600 mg clopidogrel before PCI and will undergo screening for 2C19 status within 24 hours after treatment. Randomization will occur immediately thereafter.
  • Stable and NSTEACS patients will be treated upstream with 600 mg clopidogrel and will undergo screening either before PCI or soon after (within 6 hours) revascularisation. In both scenarios randomization will occur immediately after the genotype status is known without any additional delay.

Exclusion

  • Patients who can not give informed consent or have a life expectancy of \< 1 year
  • Ongoing bleeding or bleeding diathesis or increase bleeding risk or history of bleeding in the last 2 months
  • Age \> 90
  • Previous stroke or TIA or any intracranial pathology
  • Major surgery or trauma within the previous six weeks
  • Platelet count \< 100.000 per cubic mm or HCT ,33% or Hb \< 11 gm/dL
  • Subjects with an allergy or intolerance to prasugrel or to clopidogrel
  • Planned elective cardiac or non-cardiac surgery within 1 month.
  • Current or planned therapy with coumadin anticoagulation.

Key Trial Info

Start Date :

January 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

August 1 2013

Estimated Enrollment :

522 Patients enrolled

Trial Details

Trial ID

NCT01512953

Start Date

January 1 2011

End Date

August 1 2013

Last Update

January 20 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital of Ferrara

Ferrara, ER, Italy, 44100